TVTX · Travere Therapeutics, Inc.
$50.08
-4.48% last session
End-of-day data · close of 2026-10-23
Market cap
$5B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
8.8
Dividend yield
0.0%
Beta
1.14
Avg volume
2M
Employees
0K
Daily Change %
-4.48%
5 Days Change
5.71%
10 Days Change
1.22%
30 Days Change
-12.37%
60 Days Change
-19.61%
Month to Day Change
-7.77%
Year to Day Change
37.22%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TVTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-24
Latest call per bank · past 12 months
Citigroup
Buy$85.00
+69.7% vs priceWells Fargo
Overweight$65.00
+29.8% vs priceJP Morgan
Overweight$41.00
-18.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | Guggenheim | Maintains | Buy | $75.00 → $89.00 |
| 2026-09-22 | Wedbush | Reiterates | Outperform | $76.00 |
| 2026-09-22 | HC Wainwright & Co. | Reiterates | Buy | $67.00 |
| 2026-08-10 | Evercore ISI Group | Maintains | Outperform | $68.00 → $78.00 |
| 2026-08-06 | Canaccord Genuity | Maintains | Buy | $62.00 → $70.00 |
| 2026-08-06 | Wedbush | Maintains | Outperform | $61.00 → $75.00 |
| 2026-08-05 | TD Cowen | Maintains | Buy | $60.00 → $75.00 |
| 2026-08-05 | Citigroup | Maintains | Buy | $70.00 → $85.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 17.1% below the 50-day MA ($60.41).
- bullish: Price vs 200-day MA: Trading 8.5% above the 200-day MA ($46.17).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.04) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($26.79) and high ($67.52).
TVTX Price Chart
Loading chart for TVTX…
Fundamentals
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.